- Home
- DNLI vs CNS Comparison
DNLI vs CNS Comparison
Compare DNLI & CNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- CNS
- Stock Information
- Founded
- DNLI 2013
- CNS 1986
- Country
- DNLI United States
- CNS United States
- Employees
- DNLI N/A
- CNS N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- CNS Investment Managers
- Sector
- DNLI Health Care
- CNS Finance
- Exchange
- DNLI Nasdaq
- CNS Nasdaq
- Market Cap
- DNLI 4.5B
- CNS 5.1B
- IPO Year
- DNLI 2017
- CNS 2004
- Fundamental
- Price
- DNLI $25.05
- CNS $100.45
- Analyst Decision
- DNLI Strong Buy
- CNS Hold
- Analyst Count
- DNLI 11
- CNS 3
- Target Price
- DNLI $38.90
- CNS $92.00
- AVG Volume (30 Days)
- DNLI 788.0K
- CNS 231.3K
- Earning Date
- DNLI 11-06-2024
- CNS 10-16-2024
- Dividend Yield
- DNLI N/A
- CNS 2.35%
- EPS Growth
- DNLI N/A
- CNS 0.80
- EPS
- DNLI N/A
- CNS 2.68
- Revenue
- DNLI N/A
- CNS $496,822,000.00
- Revenue This Year
- DNLI N/A
- CNS $7.84
- Revenue Next Year
- DNLI $283.75
- CNS $16.64
- P/E Ratio
- DNLI N/A
- CNS $37.47
- Revenue Growth
- DNLI 204.74
- CNS 0.21
- 52 Week Low
- DNLI $14.56
- CNS $56.04
- 52 Week High
- DNLI $33.33
- CNS $110.67
- Technical
- Relative Strength Index (RSI)
- DNLI 37.93
- CNS 51.71
- Support Level
- DNLI $26.17
- CNS $99.46
- Resistance Level
- DNLI $33.33
- CNS $106.29
- Average True Range (ATR)
- DNLI 1.64
- CNS 2.79
- MACD
- DNLI -0.13
- CNS -0.39
- Stochastic Oscillator
- DNLI 0.66
- CNS 29.59
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About CNS Cohen & Steers Inc
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for close to two thirds of its $79.3 billion in managed assets at the end of January 2024. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 42% (27%) of its managed assets (base management fees) from institutional clients, 45% (52%) from open-end funds, and 13% (21%) from closed-end funds.